Charles L. Hooper is president and co-founder of Objective Insights, Inc., a consulting firm dedicated to providing life science companies with the marketing and financial analyses they need to make informed decisions about their business opportunities. Objective Insights has been in business for 29 years and has successfully completed more than 440 projects for over seventy biopharmaceutical companies. His clients have included one- and two-person start-ups to midsized companies to Fortune 500 companies, including Akero, AstraZeneca, Biogen, Cubist (now Merck), CV Therapeutics (now Gilead), Forty Seven (now Gilead), Genentech, Gilead Sciences, Eli Lilly, Iovance, Jazz Pharmaceuticals, Merck & Co., Mirati, Novo Nordisk, Pharmacia & Upjohn (now Pfizer), Prothena, Roche, and Rocket Pharma. Before this, he held positions at NASA/Ames Research Center, Merck & Co., and Syntex Labs. He was a Visiting Fellow at Stanford’s Hoover Institution for a decade, and is a director with the Peardale-Chicago Park Fire Protection District.

Mr. Hooper has a B.S. in Computer Science Engineering from Santa Clara University and an M.S. in Engineering-Economic Systems (now Management Science Engineering) from Stanford University. He has started four companies, and his writing has appeared in many publications including the Wall Street Journal. He coauthored Making Great Decisions in Business and Life (Chicago Park Press, 2006) with economist David R. Henderson, and it has been translated into Chinese (Mandarin), Japanese, Korean, and Spanish